RxDoctor Payments DataLook up a doctor →

Scott Boyens, MD

Family Medicine · Sioux Falls, SDNPI 1700886389

Payments from drug & device makers

$6,201in general payments, 2019–2025

Across 427 payments — averaging $14.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$730
  • Novo Nordisk$614
  • Pfizer$607
  • Dexcom, Inc.$500
  • Amgen$487
  • Lilly USA, LLC$478
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,175100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,201 in reported general payments places this provider in the 95th percentile of 408 family medicine providers in South Dakota.

See all family medicine providers in South Dakota

Medicare billing

Part B allowed, 2024
$91,963
Medicare patients
344
Services billed
1,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$64,329
XareltoRivaroxaban48$50,266
EliquisApixaban53$47,214
FarxigaDapagliflozin Propanediol50$45,484
JardianceEmpagliflozin35$39,261
Xigduo XrDapaglifloz Propaned/Metformin40$31,531
TrulicityDulaglutide16$27,910
CreonLipase/Protease/Amylase21$24,131
MounjaroTirzepatide19$23,709
Synjardy XrEmpagliflozin/Metformin Hcl22$20,229
Tresiba Flextouch U-100Insulin Degludec31$18,306
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,518
LinzessLinaclotide24$14,342
Tresiba Flextouch U-200Insulin Degludec14$9,495
MyrbetriqMirabegron28$9,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$614$64,32941 claims
Boehringer IngelheimJardiance, Synjardy Xr$184$59,49057 claims
Lilly USA, LLCTrulicity, Mounjaro, Olanzapine$478$55,647109 claims
Johnson & JohnsonXarelto$112$50,26648 claims
PfizerEliquis$607$47,21453 claims
AstraZenecaFarxiga$472$45,48450 claims
AbbVieCreon, Linzess$730$38,47345 claims
GSKTrelegy Ellipta$113$14,51820 claims
Astellas Pharma US IncMyrbetriq$184$9,01828 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$13$5,30912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 family medicine providers in South Dakota.

Other family medicine in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →